GH Stock Recent News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved t.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. TIME editors then evaluated companies on key factors, including impact, innovation, ambit.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago. Featured presentations will share data supporting the utility of therapy resp.

From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)'s Medical Devices Advisory Committee has strongly recommended FDA approval of the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The recommendation signals the advisory committee panel's consensus.

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health's blood test to screen for colorectal cancer in average-risk adults. The panel meetin.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. William Blair 44th Annual Growth Stock Conference in Chicago Presentation on Tuesday, June 4 at 3:20 p.m. CT / 4:20 p.m. ET Jefferies Global Healthcare Conference in New York Presentation on Wednesday, June 5 at 5:00 p.m. ET / 2:00 p.m. PT Goldman Sachs 45th Annual Global Healthcare Conference in Miami B.

DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal amount of its 7.750% Senior Notes due 2028 (the “Additional Notes”). Trinity intends to use the net proceeds from the Offering, if consummated, together with cash on hand and/or borrowings under its corporate revolving credit facility, to (i) finance the repayment in full of its 4.550% Senior Notes due 2024 and.